NASDAQ: PETSPetmed Express Inc Stock
$1.99+0.03 (+1.53%)
Updated Jul 21, 2026
PETS Price
$1.99
Fair Value Price
$0.18
Market Cap
$42.52M
52 Week Low
$1.57
52 Week High
$4.10
P/E
-0.73x
P/B
1.47x
P/S
0.27x
PEG
N/A
Dividend Yield
N/A
Revenue
$179.02M
Earnings
-$57.29M
Gross Margin
28.1%
Operating Margin
-32.33%
Profit Margin
-32%
Debt to Equity
1.81
Operating Cash Flow
-$28M
Beta
0.9
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PETS Overview
PetMed Express, Inc., through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and other essential supplies for canines, felines, and equines. Their non-prescription offerings include products for flea and tick prevention, joint and bone care, vitamins, treats, nutritional supplements, hygiene essentials, and general pet supplies. For prescription needs, they supply heartworm and flea/tick preventatives, alongside medications for conditions such as arthritis, dermatitis, thyroid imbalances, diabetes, pain relief, and cardiovascular issues, often providing generic alternatives. Beyond pharmaceuticals, the company also retails pet food, bedding, crates, stairs, and various other accessories. PetMed Express engages with its clientele through multiple distribution channels: its official website, a dedicated mobile application, a telephone contact center, direct mail campaigns (like brochures and postcards), and television advertisements, frequently promoting its 1-800-PetMeds and PetMeds brands. The company was established in 1996 and is headquartered in Delray Beach, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PETS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important PETS news, forecast changes, insider trades & much more!
PETS News
Overview
Due Diligence Score
–
Industry Average (19)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PETS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PETS ($1.99) is overvalued by 1,024.18% relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PETS ($1.99) is not significantly undervalued (1,024.18%) relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PETS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more PETS due diligence checks available for Premium users.
Valuation
PETS fair value
Fair Value of PETS stock based on Discounted Cash Flow (DCF)
Price
$1.99
Fair Value
$0.18
Overvalued by
1,024.18%
PETS ($1.99) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PETS ($1.99) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PETS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PETS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.73x
Industry
-3.72x
Market
12.07x
PETS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.47x
Industry
42.18x
PETS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PETS's financial health
Profit margin
Revenue
$42.8M
Net Income
-$4.1M
Profit Margin
-9.5%
PETS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PETS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$81.2M
Liabilities
$52.3M
Debt to equity
1.81
PETS's short-term liabilities ($52.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PETS's short-term assets ($43.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PETS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PETS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.7M
Investing
-$720.0k
Financing
-$38.0k
PETS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PETS vs Pharmaceutical Retailer Stocks
Petmed Express Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.